company background image
ROG

Roche Holding SWX:ROG Stock Report

Last Price

CHF315.00

Market Cap

CHF259.9b

7D

-0.5%

1Y

-14.4%

Updated

12 Aug, 2022

Data

Company Financials +
ROG fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance3/6
Financial Health3/6
Dividends5/6

ROG Stock Overview

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally.

Roche Holding Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Roche Holding
Historical stock prices
Current Share PriceCHF315.00
52 Week HighCHF404.20
52 Week LowCHF298.30
Beta0.29
1 Month Change-3.14%
3 Month Change-1.25%
1 Year Change-14.39%
3 Year Change15.30%
5 Year Change30.49%
Change since IPO1,106.90%

Recent News & Updates

Shareholder Returns

ROGCH PharmaceuticalsCH Market
7D-0.5%-3.0%-0.2%
1Y-14.4%-1.0%-12.0%

Return vs Industry: ROG underperformed the Swiss Pharmaceuticals industry which returned -1% over the past year.

Return vs Market: ROG underperformed the Swiss Market which returned -12% over the past year.

Price Volatility

Is ROG's price volatile compared to industry and market?
ROG volatility
ROG Average Weekly Movement2.7%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement4.5%
10% most volatile stocks in CH Market8.1%
10% least volatile stocks in CH Market2.4%

Stable Share Price: ROG is less volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: ROG's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1896100,920Severin Schwanhttps://www.roche.com

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases.

Roche Holding Fundamentals Summary

How do Roche Holding's earnings and revenue compare to its market cap?
ROG fundamental statistics
Market CapCHF259.90b
Earnings (TTM)CHF14.29b
Revenue (TTM)CHF66.90b

17.7x

P/E Ratio

3.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ROG income statement (TTM)
RevenueCHF66.90b
Cost of RevenueCHF19.82b
Gross ProfitCHF47.09b
Other ExpensesCHF32.79b
EarningsCHF14.29b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Feb 02, 2023

Earnings per share (EPS)17.84
Gross Margin70.38%
Net Profit Margin21.36%
Debt/Equity Ratio95.9%

How did ROG perform over the long term?

See historical performance and comparison

Dividends

3.0%

Current Dividend Yield

52%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is ROG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ROG?

Other financial metrics that can be useful for relative valuation.

ROG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.3x
Enterprise Value/EBITDA11.9x
PEG Ratio2.3x

Price to Earnings Ratio vs Peers

How does ROG's PE Ratio compare to its peers?

ROG PE Ratio vs Peers
The above table shows the PE ratio for ROG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average39.5x
NOVN Novartis
8.1x3.5%CHF174.8b
VIFN Vifor Pharma
74.8x28.5%CHF11.0b
COPN Cosmo Pharmaceuticals
25.1x48.3%CHF855.2m
LLY Eli Lilly
51.4x22.2%US$292.7b
ROG Roche Holding
17.7x7.5%CHF259.9b

Price-To-Earnings vs Peers: ROG is good value based on its Price-To-Earnings Ratio (17.7x) compared to the peer average (39.5x).


Price to Earnings Ratio vs Industry

How does ROG's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

Price-To-Earnings vs Industry: ROG is expensive based on its Price-To-Earnings Ratio (17.7x) compared to the European Pharmaceuticals industry average (17.4x)


Price to Earnings Ratio vs Fair Ratio

What is ROG's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ROG PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17.7x
Fair PE Ratio43.7x

Price-To-Earnings vs Fair Ratio: ROG is good value based on its Price-To-Earnings Ratio (17.7x) compared to the estimated Fair Price-To-Earnings Ratio (43.7x).


Share Price vs Fair Value

What is the Fair Price of ROG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ROG (CHF315) is trading below our estimate of fair value (CHF972.07)

Significantly Below Fair Value: ROG is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Future Growth

How is Roche Holding forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


7.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ROG's forecast earnings growth (7.5% per year) is above the savings rate (-0.2%).

Earnings vs Market: ROG's earnings (7.5% per year) are forecast to grow slower than the Swiss market (8.8% per year).

High Growth Earnings: ROG's earnings are forecast to grow, but not significantly.

Revenue vs Market: ROG's revenue (3.7% per year) is forecast to grow slower than the Swiss market (4.3% per year).

High Growth Revenue: ROG's revenue (3.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ROG's Return on Equity is forecast to be high in 3 years time (37.5%)


Discover growth companies

Past Performance

How has Roche Holding performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


10.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ROG has high quality earnings.

Growing Profit Margin: ROG's current net profit margins (21.4%) are lower than last year (23.1%).


Past Earnings Growth Analysis

Earnings Trend: ROG's earnings have grown by 10.1% per year over the past 5 years.

Accelerating Growth: ROG's earnings growth over the past year (1%) is below its 5-year average (10.1% per year).

Earnings vs Industry: ROG earnings growth over the past year (1%) underperformed the Pharmaceuticals industry 18.2%.


Return on Equity

High ROE: ROG's Return on Equity (53.2%) is considered outstanding.


Discover strong past performing companies

Financial Health

How is Roche Holding's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: ROG's short term assets (CHF30.3B) exceed its short term liabilities (CHF27.4B).

Long Term Liabilities: ROG's short term assets (CHF30.3B) do not cover its long term liabilities (CHF30.4B).


Debt to Equity History and Analysis

Debt Level: ROG's net debt to equity ratio (72.3%) is considered high.

Reducing Debt: ROG's debt to equity ratio has increased from 83.5% to 95.9% over the past 5 years.

Debt Coverage: ROG's debt is well covered by operating cash flow (77.9%).

Interest Coverage: ROG's interest payments on its debt are well covered by EBIT (50.5x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Roche Holding current dividend yield, its reliability and sustainability?

Dividend Score

5/6

Dividend Score 5/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


2.95%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: ROG's dividend (2.95%) is higher than the bottom 25% of dividend payers in the Swiss market (1.8%).

High Dividend: ROG's dividend (2.95%) is low compared to the top 25% of dividend payers in the Swiss market (3.98%).


Stability and Growth of Payments

Stable Dividend: ROG's dividends per share have been stable in the past 10 years.

Growing Dividend: ROG's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonable payout ratio (52.1%), ROG's dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (43.5%), ROG's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Severin Schwan (55 yo)

14.42yrs

Tenure

CHF11,494,906

Compensation

Dr. Severin Schwan, Ph D., has been Chief Executive Officer of Roche Holding AG and Roche Holdings, Inc. and Roche Molecular Systems Inc. since March 2008. Dr. Schwan has been Group Chief Executive Officer...


CEO Compensation Analysis

Compensation vs Market: Severin's total compensation ($USD12.19M) is above average for companies of similar size in the Swiss market ($USD7.05M).

Compensation vs Earnings: Severin's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ROG's management team is considered experienced (3 years average tenure).


Board Members

Experienced Board: ROG's board of directors are considered experienced (6.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Roche Holding AG's employee growth, exchange listings and data sources


Key Information

  • Name: Roche Holding AG
  • Ticker: ROG
  • Exchange: SWX
  • Founded: 1896
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CHF259.904b
  • Shares outstanding: 801.09m
  • Website: https://www.roche.com

Number of Employees


Location

  • Roche Holding AG
  • Konzern Hauptsitz
  • Grenzacherstrasse 124
  • Basel
  • Basel-Stadt
  • 4070
  • Switzerland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/12 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.